Evommune, Inc. (EVMN) - Net Assets
Based on the latest financial reports, Evommune, Inc. (EVMN) has net assets worth $205.57 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($224.95 Million) and total liabilities ($19.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Evommune, Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $205.57 Million |
| % of Total Assets | 91.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Evommune, Inc. - Net Assets Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Evommune, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Evommune, Inc. (2023–2025)
The table below shows the annual net assets of Evommune, Inc. from 2023 to 2025. For live valuation and market cap data, see Evommune, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $205.57 Million | +242.52% |
| 2024-12-31 | $-144.24 Million | -85.60% |
| 2023-12-31 | $-77.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evommune, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13717800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Components | $426.65 Million | 207.55% |
| Total Equity | $205.57 Million | 100.00% |
Evommune, Inc. Competitors by Market Cap
The table below lists competitors of Evommune, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SNTEnergy Co Ltd
KO:100840
|
$858.42 Million |
|
Ratos AB (publ)
ST:RATO-B
|
$858.42 Million |
|
Zhejiang Zhongcheng Packing Material Co Ltd
SHE:002522
|
$858.89 Million |
|
Shengyuan Environmental Protection
SHE:300867
|
$858.91 Million |
|
IRB-Brasil Resseguros S.A.
SA:IRBR3
|
$858.31 Million |
|
SMU S.A
SN:SMU
|
$858.18 Million |
|
Ryerson Holding Corp
NYSE:RYI
|
$858.13 Million |
|
Synsam AB
ST:SYNSAM
|
$857.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evommune, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -144,237,000 to 205,566,000, a change of 349,803,000.
- Net loss of 68,870,000 reduced equity.
- New share issuances of 65,228,000 increased equity.
- Other factors increased equity by 353,445,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.87 Million | -33.5% |
| Share Issuances | $65.23 Million | +31.73% |
| Other Changes | $353.44 Million | +171.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evommune, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-2.58 | $23.83 | x |
| 2024-12-31 | $-4.80 | $23.83 | x |
| 2025-12-31 | $6.52 | $23.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evommune, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -529.77%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.09x
- Recent ROE (-33.50%) is below the historical average (-11.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -681.06% | 0.06x | 0.00x | $-26.28 Million |
| 2024 | 0.00% | -954.40% | 0.09x | 0.00x | $-52.38 Million |
| 2025 | -33.50% | -529.77% | 0.06x | 1.09x | $-89.43 Million |
Industry Comparison
This section compares Evommune, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $187,025,998
- Average return on equity (ROE) among peers: -94.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evommune, Inc. (EVMN) | $205.57 Million | 0.00% | 0.09x | $858.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $128.24 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $-20.80 Million | 0.00% | 0.00x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $185.59 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $28.20 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $10.03 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.66 Billion |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more